{"pmid":32192561,"title":"Pharmacy Services and the Novel Coronavirus.","text":["Pharmacy Services and the Novel Coronavirus.","Pharmacists around the world can expect to be affected by the coronavirus, especially those who provide care for older people who are at a much higher risk for grave consequences from the virus. It is critical that pharmacists maintain awareness of the evolving pandemic and access reliable information to remain familiar with developments.","Sr Care Pharm","Alderman, Chris","32192561"],"abstract":["Pharmacists around the world can expect to be affected by the coronavirus, especially those who provide care for older people who are at a much higher risk for grave consequences from the virus. It is critical that pharmacists maintain awareness of the evolving pandemic and access reliable information to remain familiar with developments."],"journal":"Sr Care Pharm","authors":["Alderman, Chris"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32192561","week":"202012|Mar 16 - Mar 22","doi":"10.4140/TCP.n.2020.146.","source":"PubMed","weight":0,"_version_":1661818360792350720,"score":6.891626,"similar":[{"pmid":32081569,"title":"Community pharmacist in public health emergencies: Quick to action against the coronavirus 2019-nCoV outbreak.","text":["Community pharmacist in public health emergencies: Quick to action against the coronavirus 2019-nCoV outbreak.","The 2019-nCoV infection that is caused by a novel strain of coronavirus was first detected in China in the end of December 2019 and declared a public health emergency of international concern by the World Health Organization on January 30, 2020. Community pharmacists in one of the first areas that had confirmed cases of the viral infection, Macau, joined the collaborative force in supporting the local health emergency preparedness and response arrangements. This paper aimed to improve the understanding of community pharmacists' role in case of 2019-CoV outbreak based on the practical experiences in consultation with the recommendations made by the International Pharmaceutical Federation on the Coronavirus 2019-nCoV outbreak.","Res Social Adm Pharm","Ung, Carolina Oi Lam","32081569"],"abstract":["The 2019-nCoV infection that is caused by a novel strain of coronavirus was first detected in China in the end of December 2019 and declared a public health emergency of international concern by the World Health Organization on January 30, 2020. Community pharmacists in one of the first areas that had confirmed cases of the viral infection, Macau, joined the collaborative force in supporting the local health emergency preparedness and response arrangements. This paper aimed to improve the understanding of community pharmacists' role in case of 2019-CoV outbreak based on the practical experiences in consultation with the recommendations made by the International Pharmaceutical Federation on the Coronavirus 2019-nCoV outbreak."],"journal":"Res Social Adm Pharm","authors":["Ung, Carolina Oi Lam"],"date":"2020-02-22T11:00:00Z","year":2020,"_id":"32081569","week":"20208|Feb 17 - Feb 23","doi":"10.1016/j.sapharm.2020.02.003","keywords":["2019-nCoV","Community pharmacy","Macau","Outbreak","Pharmacist"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661359647386238976,"score":82.68798},{"pmid":32052373,"title":"Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients.","text":["Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients.","A global health emergency has been declared by the World Health Organization as the 2019-nCoV outbreak spreads across the world, with confirmed patients in Canada. Patients infected with 2019-nCoV are at risk for developing respiratory failure and requiring admission to critical care units. While providing optimal treatment for these patients, careful execution of infection control measures is necessary to prevent nosocomial transmission to other patients and to healthcare workers providing care. Although the exact mechanisms of transmission are currently unclear, human-to-human transmission can occur, and the risk of airborne spread during aerosol-generating medical procedures remains a concern in specific circumstances. This paper summarizes important considerations regarding patient screening, environmental controls, personal protective equipment, resuscitation measures (including intubation), and critical care unit operations planning as we prepare for the possibility of new imported cases or local outbreaks of 2019-nCoV. Although understanding of the 2019-nCoV virus is evolving, lessons learned from prior infectious disease challenges such as Severe Acute Respiratory Syndrome will hopefully improve our state of readiness regardless of the number of cases we eventually manage in Canada.","Can J Anaesth","Wax, Randy S","Christian, Michael D","32052373"],"abstract":["A global health emergency has been declared by the World Health Organization as the 2019-nCoV outbreak spreads across the world, with confirmed patients in Canada. Patients infected with 2019-nCoV are at risk for developing respiratory failure and requiring admission to critical care units. While providing optimal treatment for these patients, careful execution of infection control measures is necessary to prevent nosocomial transmission to other patients and to healthcare workers providing care. Although the exact mechanisms of transmission are currently unclear, human-to-human transmission can occur, and the risk of airborne spread during aerosol-generating medical procedures remains a concern in specific circumstances. This paper summarizes important considerations regarding patient screening, environmental controls, personal protective equipment, resuscitation measures (including intubation), and critical care unit operations planning as we prepare for the possibility of new imported cases or local outbreaks of 2019-nCoV. Although understanding of the 2019-nCoV virus is evolving, lessons learned from prior infectious disease challenges such as Severe Acute Respiratory Syndrome will hopefully improve our state of readiness regardless of the number of cases we eventually manage in Canada."],"journal":"Can J Anaesth","authors":["Wax, Randy S","Christian, Michael D"],"date":"2020-02-14T11:00:00Z","year":2020,"_id":"32052373","week":"20207|Feb 10 - Feb 16","doi":"10.1007/s12630-020-01591-x","keywords":["COVID-19"],"source":"PubMed","locations":["Canada"],"countries":["Canada"],"countries_codes":["CAN|Canada"],"topics":["Treatment"],"weight":1,"_version_":1661359647254118403,"score":62.87947},{"pmid":32196387,"title":"Strategies to Inform Allocation of Stockpiled Ventilators to Healthcare Facilities During a Pandemic.","text":["Strategies to Inform Allocation of Stockpiled Ventilators to Healthcare Facilities During a Pandemic.","During a severe pandemic, especially one causing respiratory illness, many people may require mechanical ventilation. Depending on the extent of the outbreak, there may be insufficient capacity to provide ventilator support to all of those in need. As part of a larger conceptual framework for determining need for and allocation of ventilators during a public health emergency, this article focuses on the strategies to assist state and local planners to allocate stockpiled ventilators to healthcare facilities during a pandemic, accounting for critical factors in facilities' ability to make use of additional ventilators. These strategies include actions both in the pre-pandemic and intra-pandemic stages. As a part of pandemic preparedness, public health officials should identify and query healthcare facilities in their jurisdiction that currently care for critically ill patients on mechanical ventilation to determine existing inventory of these devices and facilities' ability to absorb additional ventilators. Facilities must have sufficient staff, space, equipment, and supplies to utilize allocated ventilators adequately. At the time of an event, jurisdictions will need to verify and update information on facilities' capacity prior to making allocation decisions. Allocation of scarce life-saving resources during a pandemic should consider ethical principles to inform state and local plans for allocation of ventilators. In addition to ethical principles, decisions should be informed by assessment of need, determination of facilities' ability to use additional ventilators, and facilities' capacity to ensure access to ventilators for vulnerable populations (eg, rural, inner city, and uninsured and underinsured individuals) or high-risk populations that may be more susceptible to illness.","Health Secur","Koonin, Lisa M","Pillai, Satish","Kahn, Emily B","Moulia, Danielle","Patel, Anita","32196387"],"abstract":["During a severe pandemic, especially one causing respiratory illness, many people may require mechanical ventilation. Depending on the extent of the outbreak, there may be insufficient capacity to provide ventilator support to all of those in need. As part of a larger conceptual framework for determining need for and allocation of ventilators during a public health emergency, this article focuses on the strategies to assist state and local planners to allocate stockpiled ventilators to healthcare facilities during a pandemic, accounting for critical factors in facilities' ability to make use of additional ventilators. These strategies include actions both in the pre-pandemic and intra-pandemic stages. As a part of pandemic preparedness, public health officials should identify and query healthcare facilities in their jurisdiction that currently care for critically ill patients on mechanical ventilation to determine existing inventory of these devices and facilities' ability to absorb additional ventilators. Facilities must have sufficient staff, space, equipment, and supplies to utilize allocated ventilators adequately. At the time of an event, jurisdictions will need to verify and update information on facilities' capacity prior to making allocation decisions. Allocation of scarce life-saving resources during a pandemic should consider ethical principles to inform state and local plans for allocation of ventilators. In addition to ethical principles, decisions should be informed by assessment of need, determination of facilities' ability to use additional ventilators, and facilities' capacity to ensure access to ventilators for vulnerable populations (eg, rural, inner city, and uninsured and underinsured individuals) or high-risk populations that may be more susceptible to illness."],"journal":"Health Secur","authors":["Koonin, Lisa M","Pillai, Satish","Kahn, Emily B","Moulia, Danielle","Patel, Anita"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32196387","week":"202012|Mar 16 - Mar 22","doi":"10.1089/hs.2020.0028","keywords":["Allocation","COVID-19","Pandemic","Public health preparedness/response","Ventilator"],"source":"PubMed","weight":0,"_version_":1661818360794447873,"score":62.11437},{"pmid":32160942,"title":"Novel coronavirus disease (COVID-19) outbreak: Now is the time to refresh pandemic plans.","text":["Novel coronavirus disease (COVID-19) outbreak: Now is the time to refresh pandemic plans.","This article outlines practical steps that businesses can take now to prepare for a pandemic. Given the current growing spread of coronavirus disease 2019 (COVID-19) around the world, it is imperative that businesses review their pandemic plans and be prepared in case this epidemic expands and affects more people and communities. Preparing for a potential infectious disease pandemic from influenza or a novel corona virus is an essential component of a business continuity plan, especially for businesses that provide critical healthcare and infrastructure services. Although many businesses and organisations have a pandemic plan or address pandemic preparedness in their business continuity plans, few have recently tested and updated their plans. Pandemics can not only interrupt an organisation's operations and compromise long-term viability of an enterprise, but also disrupt the provision of critical functions. Businesses that regularly test and update their pandemic plan can significantly reduce harmful impacts to the business, play a key role in protecting employees' and customers' health and safety, and limit the negative impact of a pandemic on the community and economy.","J Bus Contin Emer Plan","Koonin, Lisa M","32160942"],"abstract":["This article outlines practical steps that businesses can take now to prepare for a pandemic. Given the current growing spread of coronavirus disease 2019 (COVID-19) around the world, it is imperative that businesses review their pandemic plans and be prepared in case this epidemic expands and affects more people and communities. Preparing for a potential infectious disease pandemic from influenza or a novel corona virus is an essential component of a business continuity plan, especially for businesses that provide critical healthcare and infrastructure services. Although many businesses and organisations have a pandemic plan or address pandemic preparedness in their business continuity plans, few have recently tested and updated their plans. Pandemics can not only interrupt an organisation's operations and compromise long-term viability of an enterprise, but also disrupt the provision of critical functions. Businesses that regularly test and update their pandemic plan can significantly reduce harmful impacts to the business, play a key role in protecting employees' and customers' health and safety, and limit the negative impact of a pandemic on the community and economy."],"journal":"J Bus Contin Emer Plan","authors":["Koonin, Lisa M"],"date":"2020-03-13T11:00:00Z","year":2020,"_id":"32160942","week":"202011|Mar 09 - Mar 15","source":"PubMed","topics":["General Info"],"weight":1,"_version_":1661359647895846912,"score":54.920856},{"pmid":32162896,"title":"Possible therapeutic role of a highly standardized mixture of active compounds derived from cultured Lentinula edodes mycelia (AHCC) in patients infected with 2019 novel coronavirus.","text":["Possible therapeutic role of a highly standardized mixture of active compounds derived from cultured Lentinula edodes mycelia (AHCC) in patients infected with 2019 novel coronavirus.","The outbreak of SARS-CoV-2 disease (COVID-19) is currently, March 2020, affecting more than 100000 people worldwide and, according to the WHO (World Health Organization), a pandemic is shortly expected. The virus infects the lower respiratory tract and causes severe pneumonia and mortality in approximately 10% and 3-5%, respectively, of cases, mainly among the elderly and/or people affected by other diseases. AHCC is an alpha-glucan-based standardized mushroom extract that has been extensively investigated as an immunostimulant both in animals and/or in humans affected by West Nile virus, influenza virus, avian influenza virus, hepatitis C virus, papillomavirus, herpes virus, hepatitis B virus and HIV by promoting a regulated and protective immune response. Although the efficacy of AHCC has not yet been specifically evaluated with respect to SARS-CoV-2 disease, its action in promoting a protective response to a wide range of viral infections, and the current absence of effective vaccines, could support its use in the prevention of diseases provoked by human pathogenic coronavirus, including COVID-19.","Minerva Gastroenterol Dietol","Di Pierro, Francesco","Bertuccioli, Alexander","Cavecchia, Ilaria","32162896"],"abstract":["The outbreak of SARS-CoV-2 disease (COVID-19) is currently, March 2020, affecting more than 100000 people worldwide and, according to the WHO (World Health Organization), a pandemic is shortly expected. The virus infects the lower respiratory tract and causes severe pneumonia and mortality in approximately 10% and 3-5%, respectively, of cases, mainly among the elderly and/or people affected by other diseases. AHCC is an alpha-glucan-based standardized mushroom extract that has been extensively investigated as an immunostimulant both in animals and/or in humans affected by West Nile virus, influenza virus, avian influenza virus, hepatitis C virus, papillomavirus, herpes virus, hepatitis B virus and HIV by promoting a regulated and protective immune response. Although the efficacy of AHCC has not yet been specifically evaluated with respect to SARS-CoV-2 disease, its action in promoting a protective response to a wide range of viral infections, and the current absence of effective vaccines, could support its use in the prevention of diseases provoked by human pathogenic coronavirus, including COVID-19."],"journal":"Minerva Gastroenterol Dietol","authors":["Di Pierro, Francesco","Bertuccioli, Alexander","Cavecchia, Ilaria"],"date":"2020-03-13T11:00:00Z","year":2020,"_id":"32162896","week":"202011|Mar 09 - Mar 15","doi":"10.23736/S1121-421X.20.02697-5","source":"PubMed","locations":["avian"],"topics":["Treatment"],"weight":1,"_version_":1661359647882215425,"score":52.31211}]}